nigel-stevenson
gillem-tulloch
mark-webb
celltrion-inc
kuangchi-science
iflytek
travelsky-tech
unigroup-guoxin-microelectronics
celltrion-healthcare
wuxi-biologics
tongcheng-travel
advanced-micro-fabrication-equipment
china-merchants-expressway-network
hangzhou-tigermed-consulting
yunnan-energy-new-mat
naura-tech
trent-ltd
kuang-chi-technologies
supcon-technology
dentsu-group
zjld-group
chaozhou-three-circle-group
coromandel-int
crrc-times-electric
huizhou-desay-sv-automotive
pantai-indah-kapuk-dua
seatrium
shandong-hi-speed
shenzhen-longsys-electronics
sk-biopharma
sunway
evergreen-marine
hotai-motor
samsung-heavy-industries
shandong-gold-mining
sona-blw-precision-forgings
Insights
1 December, 2023
NEWSLETTER: EVERGRANDE (3333 HK)
Never profitable
Fredrik Oeqvist
Evergrande’s much delayed and recently published 2021 annual report makes clear that it significantly overstated revenue and earnings – most likely for many years. Contrary to what some people think, Evergrande was not so much a victim of tightened liquidity or a COVID-induced property market downturn; its problems were far more fundamental – there were never any profits....
Read More
18 August, 2020
NEWSLETTER: COMING HOME?
Watch out for the privatisation “squeeze out”
Gillem Tulloch
The proposed Holding Foreign Companies Accountable Act could force hundreds of Chinese companies listed on US exchanges to delist over the next few years. For many large companies, seeking a secondary listing in Hong Kong or the mainland is a sensible insurance policy. However, investors should be wary of companies which decide to privatise and then relist. Our analysis of...
Read More